In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Tums battles heartburn and climate change with new biobased packaging
In Missouri, the multinational behind Tums has partnered with Pretium Packaging and LyondellBasell to create a biobased bottle for the antacid.
At the recent...
Vegan Society certifies interior of Mercedes-Benz GLC
In Germany, Mercedes-Benz’s GLC model has become the first car to have an interior certified by the Vegan Society. Vegan materials were used throughout the...
Wooden Bentley replica finds a home in Boca Raton
In Boca Raton, the Auto Sport Florida group has acquired a wooden replica of the original Bentley Continental GT, with sculpted wood being used...